CDDO-Me increases sensitivity, decreases resistance to Paclitaxel chemotherapy, and increases apoptosis of cancer cells by reducing STAT3-induced expression of the anti-apoptotic genes in OC cell lines [116]. Here, STAT3 is linked to cancer.